NovoCure Limited (NVCR) Is At $21.05 Formed Wedge; Factset Research Systems Has 1.08 Sentiment

NovoCure Limited (NVCR) formed wedge up with $22.52 target or 7.00% above today’s $21.05 share price. NovoCure Limited (NVCR) has $1.88 billion valuation. The stock decreased 2.09% or $0.45 during the last trading session, reaching $21.05. About 427,069 shares traded. NovoCure Limited (NASDAQ:NVCR) has declined 0.43% since February 21, 2017 and is downtrending. It has underperformed by 17.13% the S&P500.

FactSet Research Systems Inc. provides integrated financial information and data analytical applications to the investment community in the United States, Europe, and the Asia Pacific. The company has market cap of $7.83 billion. The companyÂ’s applications suite offers tools and resources, including firm and industry analyses; full screening tools; portfolio analysis; risk profiles; alpha-testing; portfolio optimization; and research management solutions. It has a 30.32 P/E ratio. FactSet Research Systems Inc. delivers insight and information to investment professionals through its analytics, services, contents, and technologies.

Analysts await NovoCure Limited (NASDAQ:NVCR) to report earnings on February, 22 before the open. They expect $-0.14 EPS, up 46.15% or $0.12 from last year’s $-0.26 per share. After $-0.13 actual EPS reported by NovoCure Limited for the previous quarter, Wall Street now forecasts 7.69% negative EPS growth.

Among 5 analysts covering NovoCure (NASDAQ:NVCR), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. NovoCure had 6 analyst reports since October 27, 2015 according to SRatingsIntel. The rating was initiated by Wedbush on Tuesday, October 27 with “Outperform”. The firm has “Outperform” rating by Wedbush given on Friday, July 29. The stock has “Overweight” rating by JP Morgan on Tuesday, October 27. The stock of NovoCure Limited (NASDAQ:NVCR) earned “Market Outperform” rating by JMP Securities on Tuesday, October 27. The firm has “Hold” rating given on Wednesday, December 2 by Deutsche Bank. Barclays Capital initiated NovoCure Limited (NASDAQ:NVCR) on Tuesday, January 19 with “Underweight” rating.

Ratings analysis reveals 0 of FactSet’s analysts are positive. Out of 2 Wall Street analysts rating FactSet, 0 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. The lowest target is $164.0 while the high is $180.0. The stock’s average target of $172 is -14.30% below today’s ($200.71) share price. FDS was included in 2 notes of analysts from August 26, 2016. As per Friday, August 26, the company rating was initiated by Macquarie Research. The rating was downgraded by Barclays Capital on Tuesday, January 10 to “Underweight”.

Analysts await FactSet Research Systems Inc. (NYSE:FDS) to report earnings on March, 27. They expect $2.05 EPS, up 13.26% or $0.24 from last year’s $1.81 per share. FDS’s profit will be $79.99 million for 24.48 P/E if the $2.05 EPS becomes a reality. After $2.04 actual EPS reported by FactSet Research Systems Inc. for the previous quarter, Wall Street now forecasts 0.49% EPS growth.

Bares Capital Management Inc. holds 5.46% of its portfolio in FactSet Research Systems Inc. for 672,267 shares. Raub Brock Capital Management Lp owns 94,088 shares or 4.34% of their US portfolio. Moreover, Saybrook Capital Nc has 4% invested in the company for 45,179 shares. The New York-based American Capital Management Inc has invested 3.16% in the stock. Dock Street Asset Management Inc, a Connecticut-based fund reported 39,033 shares.